Khiron Appoints Former DEA Chief of Pharmaceutical Investigations to Advisory Board
(Thomson Reuters ONE) -
TORONTO, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Khiron Life Sciences Corp. ("Khiron"
or the "Company") reports the appointment of Mr. Matthew Murphy, the former U.S.
Drug Enforcement Administration ("DEA") Chief of Pharmaceutical Investigations,
to the Advisory Board of the Company.
Advisory Board Appointment
Mr. Murphy is an executive leader with broad based domestic and international
expertise in both the federal and private sectors. As a Career Special Agent (25
years) with the DEA, he served in a multitude of positions prior to founding the
Pharma Compliance Group (PCG). Mr. Murphy is an internationally recognized
security expert in the fields of drug law enforcement, risk assessment and
system development, regulatory compliance, and training. He currently serves as
President of PCG, which consults to US based controlled substance manufacturers,
distributors, and retail pharmacy entities to ensure pharmaceutical regulatory
compliance. Mr. Murphy will support the Company by advising on the
implementation of closed loop systems to prevent product diversion and to
enhance protocols across Khiron's plant to patient value chain.
Commentary
Mr. Matthew Murphy, comments: "As a leader in compliance enforcement in the
early days of the current global opiate crisis, I strived to hold all parties
accountable and create a safer system for all participants. As that situation
has sadly deteriorated, it has become clear to me it is time for alternative
solutions. While observing the evolution of the global legal medical cannabis
market as well as Colombia's entrance, I firmly believe Khiron embodies best in
class approaches to quality production and security within a robust federal
regulatory framework."
Mr. Alvaro Torres, President and CEO of Khiron, comments: "We are very pleased
to welcome Mr. Murphy to the advisory board. Mr. Murphy is highly regarded by
both his former peers at the DEA and throughout private industry. He is an
excellent addition to our team. His appointment is a testament to our commitment
of ensuring regulatory compliance and world-class security measures consistent
with the most stringent requirements for controlled substances in every
jurisdiction where we operate."
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is a Canadian integrated medical cannabis company
with its core operations in Colombia. Khiron combines leading international
scientific expertise, agricultural advantages, and branded product market
entrance experience to address the unmet medical needs in a market of over 620
million people in Latin America.
On behalf of the Board of Directors
"Alvaro Torres"
Chief Executive Officer
Direct: +57 (320) 4950326
Email: aftorres(at)khiron.ca
"Darren Collins"
Chief Financial Officer
Direct: +1 (705) 527 3564
Email: dcollins(at)khiron.ca
Further information on the Company can be accessed through the link below:
www.khiron.ca
FORWARD LOOKING INFORMATION This press release contains forward-looking
information based on current expectations. These statements should not be read
as guarantees of future performance or results. Such statements involve known
and unknown risks, uncertainties and other factors that may cause actual
results, performance or achievements to be materially different from those
implied by such statements. Although such statements are based on management's
reasonable assumptions, Khiron assumes no responsibility to update or revise
forward looking information to reflect new events or circumstances unless
required by law. Although the Company believes that the expectations and
assumptions on which the forward-looking statements are based are reasonable,
undue reliance should not be placed on the forward-looking statements because
the Company can give no assurance that they will prove to be correct. Since
forward looking statements address future events and conditions, by their very
nature they involve inherent risks and uncertainties. These statements speak
only as of the date of this press release. Actual results could differ
materially from those currently anticipated due to a number of factors and
risks. This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such forward looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Khiron Life Sciences Corp. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 29.09.2017 - 17:27 Uhr
Sprache: Deutsch
News-ID 561927
Anzahl Zeichen: 5619
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 313 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Khiron Appoints Former DEA Chief of Pharmaceutical Investigations to Advisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
Khiron Life Sciences Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
